INOVIO prices $20M public offering of stock and warrants to fund DNA medicine development.

INOVIO Pharmaceuticals announced a public offering of over 21 million shares and warrants to raise approximately $20 million before expenses. The offering includes common stock and warrants exercisable at $1.10 per share, priced at $0.95 combined. Piper Sandler manages the deal, expected to close by July 31, 2026. The funds will support INOVIO's work on DNA medicines targeting HPV-related diseases, cancer, and infectious diseases.